Sartanbiphenyl has broad prospects and few domestic companies

The chemical name of Sartanbiphenyl is 2-cyano-4′-methylbiphenyl, CAS number is 114772-53-1, chemical formula is C14H11N, molecular weight is 381.37, appearance is white or off-white crystalline powder, it is insoluble in Water, soluble in methanol, ethanol, THF, benzene, toluene, heptane and other organic solvents.

Although there are many technological methods for preparing sartanbiphenyl, the more mature method for synthesizing sartanbiphenyl in industrial production is the Grignard reagent method, which uses o-chlorobenzonitrile as the starting material, and p-chlorotoluene, Tetrahydrofuran and other reagents are used to synthesize sartanbiphenyl through Suzuki coupling reaction. The raw materials used include o-chlorobenzonitrile, p-chlorotoluene, tetrahydrofuran, magnesium powder, hydrochloric acid, sodium carbonate, etc.

Sartan biphenyl is the mother core of most sartan drugs and has been widely used in the synthesis of new sartan antihypertensive drugs, such as losartan potassium, valsartan, irbesartan, telmisartan, etc. Sartan drugs are selective angiotensin II receptor antagonists with long-lasting effects, good tolerance, and high receptor selectivity. They have been widely used in clinical hypertension and other cardiorenal diseases at home and abroad. prevention and control.

Although sartanbiphenyl is an important intermediate for losartan potassium, valsartan, irbesartan and other products, the market capacity of sartanbiphenyl is relatively small. According to the “2023-2027 Sartanbiphenyl Industry In-depth Market Research and Investment Strategy Suggestions Report released by the Industrial Research Center, In 2022, domestic demand for sartanbiphenyl is only 1,400 tons.

In 2019, affected by the “valsartan incident” of Zhejiang Huahai Pharmaceutical Co., Ltd. and the Yancheng explosion, the domestic sartanbiphenyl market supply was tight and market competition was relatively relaxed. In the fourth quarter of 2020, with the completion of the technical transformation of Zhejiang Huahai Pharmaceutical Co., Ltd., its sartanbiphenyl products re-entered the market, coupled with the commissioning of new production capacity by Zhejiang Tianyu Pharmaceutical Co., Ltd. and other companies, domestic sartanbiphenyl products There is an imbalance between supply and demand in the industry, market competition has intensified, and price wars between companies have intensified. At this stage, domestic sartanbiphenyl companies include Zhejiang Tianyu Pharmaceutical Co., Ltd., Zhejiang Huahai Pharmaceutical Co., Ltd., Xinxiang Sanxin Technology Co., Ltd., Yancheng Donggang Pharmaceutical Chemical Development Co., Ltd., and Xinxiang Huaxing Biotechnology Co., Ltd. The company has five enterprises.

Industry analysts said that in the future, as my country’s aging population deepens, the demand for sartan drugs will further increase. In addition, in the national centralized procurement, a number of sartan drugs have entered the centralized procurement drug catalog, including valsartan, losartan, irbesartan, candesartan, olmesartan, and telmisartan. As sartan drugs enter the national centralized procurement, the demand for sartan biphenyl will further expand.